Skip to content

CalAmp CAMP Return on equity

Return on equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-67.6%-20.3pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-45.6%-66.1pp
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-28.3%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-379.5%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-97.3%-27.3pp
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-34.3%

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Calculated from CalAmp’s reported figures.

Based on trailing twelve months.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's return on equity?
CalAmp (CAMP) reported return on equity of -209.3% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.